HCW Biologics Inc. Common Stock (HCWB) Stock Price

HCWBStock

$3.43−89.94%52W

Market Cap$6.30M

P/E—

PEG Ratio—

Div yield—

Beta2.40

HCWB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.34%

Price vs S&P 500 (4W)1.15%

VGM Score38.67

Book Value / Share (Quarterly)$5.13

P/TBV (Annual)1.11x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-79.94%

Cash Flow / Share (Quarterly)$-10.20

Price vs S&P 500 (YTD)-53.99%

Gross Margin (TTM)99.42%

Net Profit Margin (TTM)34.42%

EPS (TTM)$-8.07

10-Day Avg Trading Volume0.27M

EPS Excl Extra (TTM)$-8.07

Revenue Growth (5Y)-57.90%

EPS (Annual)$-22.77

ROI (Annual)-83.14%

Gross Margin (Annual)19.99%

Net Profit Margin (5Y Avg)-3418.02%

Cash / Share (Quarterly)$1.09

Revenue Growth QoQ (YoY)-93.16%

ROA (Last FY)-32.46%

Revenue Growth TTM (YoY)-98.69%

EBITD / Share (TTM)$-2.53

ROE (5Y Avg)-115.76%

Operating Margin (TTM)11.72%

Cash Flow / Share (Annual)$-24.50

P/B Ratio0.81x

P/B Ratio (Quarterly)0.42x

Net Income / Employee (Annual)$-318,400

EV / Revenue (TTM)1.52x

Net Interest Coverage (TTM)-4.76x

ROA (TTM)-8.63%

EPS Incl Extra (Annual)$-22.77

Current Ratio (Annual)0.11x

Quick Ratio (Quarterly)0.07x

3-Month Avg Trading Volume1.52M

52-Week Price Return-89.94%

Revenue / Employee (TTM)$263,100

Tangible BV / Share (Quarterly)$0.66

P/S Ratio (Annual)86.13x

Asset Turnover (Annual)0.00x

52-Week High$38.16

Operating Margin (5Y Avg)-3324.26%

EPS Excl Extra (Annual)$-22.77

CapEx CAGR (5Y)-29.10%

26-Week Price Return0.59%

Quick Ratio (Annual)0.10x

13-Week Price Return-72.65%

Total Debt / Equity (Annual)2.46x

Current Ratio (Quarterly)0.09x

Enterprise Value$10.02M

Revenue / Share Growth (5Y)6.17%

Asset Turnover (TTM)0.24x

Revenue / Employee (Annual)$2,200

Pretax Margin (Annual)-14677.69%

Cash / Share (Annual)$3.57

3-Month Return Std Dev122.13%

Net Income / Employee (TTM)$-91,600

EBITDA Interim CAGR (5Y)0.07%

ROE (Last FY)-287.90%

Net Interest Coverage (Annual)0.99x

EPS Basic Excl Extra (Annual)$-22.77

Receivables Turnover (TTM)81.03x

Total Debt / Equity (Quarterly)1.14x

EPS Incl Extra (TTM)$-8.07

Receivables Turnover (Annual)0.18x

ROI (TTM)38.26%

P/S Ratio (TTM)0.71x

Pretax Margin (5Y Avg)-3418.02%

Revenue / Share (Annual)$0.16

Tangible BV / Share (Annual)$1.04

Price vs S&P 500 (52W)-108.49%

Year-to-Date Return-41.17%

5-Day Price Return48.48%

EPS Normalized (Annual)$-22.77

ROA (5Y Avg)-55.06%

Net Profit Margin (Annual)-14677.69%

Month-to-Date Return7.19%

Cash Flow / Share (TTM)$-0.52

EBITD / Share (Annual)$-21.35

Operating Margin (Annual)-14201.49%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-61.80%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-8.07

P/TBV (Quarterly)1.75x

P/B Ratio (Annual)0.95x

Pretax Margin (TTM)39.45%

Book Value / Share (Annual)$5.06

Price vs S&P 500 (13W)-74.60%

Beta2.40x

Revenue / Share (TTM)$7.27

ROE (TTM)98.31%

52-Week Low$1.50

vGradeA

gGradeF

mGradeD

vgmGradeD

HCWB Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 14, 2026	-$1.98	-$11.58	-484.85%(-$9.60)
Q1 2026	May 14, 2026	-$2.64	$2.22	+184.09%(+$4.86)
Q4 2025	Mar 31, 2026	-$5.04	-$6.12	-21.43%(-$1.08)
Q3 2025	Nov 14, 2025	$9.48	-$12.12	-227.85%(-$21.60)
Q2 2025	Aug 18, 2025	$10.80	-$40.74	-477.22%(-$51.54)

HCWB Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
HCWBHCW Biologics Inc. Common Stock	A	F	D	$3.43
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About HCW Biologics Inc. Common Stock

HCW Biologics is a clinical-stage biopharmaceutical company developing immunotherapies to treat age-related diseases by targeting chronic inflammation. The company uses its proprietary TOBI discovery platform to generate two lead candidates: HCW9218, which neutralizes growth factors and stimulates immune cells, and HCW9302, which activates regulatory T cells to reduce inflammation. This approach targets the inflammation-aging link to potentially extend healthspan across multiple indications.